Influenza Surveillance in a Pandemic
ECDC has had a group from EU countries and its partners (WHO and EMEA) looking at the issues around how surveillance (epidemiological and virological) will function in a pandemic. This is a difficult area as simultaneously there will be heightened demand for information for action and situation reports while at the same time clinical systems that usually provide information are likely to be prejudiced by excessive demand, pressure on staff and staff sickness.
There is also a need to distinguish targeted surveillance, answering key questions which will guide or trigger action: has the virus arrived in our country what is the case fatality rate are antivirals helping what is the spectrum of disease etc from the vital need of managers for more general situation monitoring.
These and other issues are discussed in the paper along with recommended objectives and a workplan for ECDC and its partners.
Smallpox - Annual Epidemiological Report for 2018
13 Nov 2019 - Smallpox was declared eradicated in 1980. There were no reports of confirmed or possible smallpox in the EU/EEA or other countries for 2018.
Tularaemia Annual Epidemiological Report for 2018
12 Nov 2019 - For 2018, 18 countries in the EU/EEA reported 441 cases of tularaemia, 358 (81%) of which were confirmed. The EU/EEA notification rate for 2018 was 0.07 cases per 100 000 population. The male-to-female ratio was 1.7:1. As in previous years, the notification rate among males was higher in most age groups except for the age groups between 5 and 24 years. Notification rates increased with age and peaked at 45–64 years.
Influenza virus characterisation, October 2019
11 Nov 2019 - This is the first report for the 2019–20 influenza season. As of week 44/2019, 1 138 influenza detections across the WHO European Region had been reported; 80% type A viruses, with A(H3N2) prevailing over A(H1N1)pdm09, and 20% type B viruses, with 26 of 27 (96%) ascribed to a lineage being B/Victoria.